BioCentury | Apr 2, 2020
Distillery Therapeutics

CDC42BPA inhibition for high-grade serous ovarian carcinoma

...CATEGORY: Cancer INDICATION: Ovarian cancer Inhibition of CDC42BPA alone or in combination with carboplatin and PAK1...
...inhibitors in patient-derived xenograft (PDX) mouse models. TARGET/MARKER/PATHWAY: CDC42 binding protein kinase α (CDC42BPA); p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1...
...James S. Duncan, Fox Chase Cancer Center, Philadelphia, Pa. email: james.duncan2@fccc.edu Claire Quang Fox Chase Cancer Center p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1...
BioCentury | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | May 25, 2018
Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
BioCentury | May 24, 2018
Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
BioCentury | Mar 20, 2018
Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays CRISPR-based screening in human cells could help identify the therapeutic targets of small molecules. The method involved three steps: generating in-frame mutations in human cell lines by engineering them to express CRISPR-associated...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Gastrointestinal

...INDICATION: Colitis Patient sample and mouse studies suggest inhibiting PAK1 and PAK2 could help treat colitis...
...identifying and testing inhibitors targeting PAK1 or PAK2 in additional models of colitis. TARGET/MARKER/PATHWAY: p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1...
...M. Haigis, Beth-Israel Deaconess Medical Center, Boston, Mass. email: khaigis@bidmc.harvard.edu Allison Johnson Beth Israel Deaconess Medical Center p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) p21...
BioCentury | Nov 6, 2017
Distillery Therapeutics

Cancer

...and MEK inhibitors, siRNA targeting PAK1, shRNA targeting PAK4, a retroviral vector encoding an inactive PAK1...
...a PAK1 inhibitor in preclinical testing to treat central nervous system (CNS) disorders. TARGET/MARKER/PATHWAY: p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1...
...2017 doi:10.1038/nature24040 CONTACT: Wei Guo, University of Pennsylvania, Philadelphia, Pa. email: guowei@sas.upenn.edu Hongjiang Li University of Pennsylvania BRAF MEK p21 protein (Cdc42 Rac)-activated kinase 1 (PAK1) p21...
BioCentury | May 19, 2017
Strategy

Contracting 2.0

Pricing doesn’t always cause business discontinuities -- but it’s always the double-edged sword at the center of the action, helping innovators and hobbling laggards. Discount brokers revolutionized consumer investing; discounted long-distance ultimately destroyed AT&T. Price...
BioCentury | Dec 16, 2016
Company News

Harvoni sales and marketing update

Express Scripts said it will expand the formulary of its Hepatitis Cure Value Program to include Gilead’s Harvoni ledipasvir/sofosbuvir. As part of an HCV pricing war, Harvoni had been kept out in favor of exclusive...
Items per page:
1 - 10 of 143